Clinical trial diversity: FDA pushes real-world evidence, diffusion of trial sites

Clinical trial diversity: FDA pushes real-world evidence, diffusion of trial sites

Source: 
RAPS.org
snippet: 

Real-world evidence, post-marketing studies, and migrating clinical trial sites into underserved communities are all strategies the U.S. Food and Drug Administration (FDA) is pushing to help increase data on the outcomes of minority patients, according to Amy Abernethy, MD, PhD, the agency’s principal deputy commissioner.